Citigroup’s Neurogene NGNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $18.7K | Buy |
930
+176
| +23% | +$3.41K | ﹤0.01% | 4849 |
|
|
2025
Q4 | $15.5K | Buy |
754
+365
| +94% | +$9.09K | ﹤0.01% | 4931 |
|
|
2025
Q3 | $6.74K | Sell |
389
-3,186
| -89% | -$64K | ﹤0.01% | 5141 |
|
|
2025
Q2 | $53.4K | Sell |
3,575
-5,001
| -58% | -$78.5K | ﹤0.01% | 4721 |
|
|
2025
Q1 | $100K | Buy |
8,576
+476
| +6% | +$8.27K | ﹤0.01% | 4598 |
|
|
2024
Q4 | $185K | Buy |
8,100
+638
| +9% | +$23.7K | ﹤0.01% | 4465 |
|
|
2024
Q3 | $313K | Buy |
7,462
+5,187
| +228% | +$201K | ﹤0.01% | 4049 |
|
|
2024
Q2 | $82.8K | Sell |
2,275
-15,246
| -87% | -$538K | ﹤0.01% | 4310 |
|
|
2024
Q1 | $892K | Buy |
+17,521
| New | +$585K | ﹤0.01% | 3122 |
|
|
2023
Q1 | – | Sell |
-14
| Closed | -$137 | – | 5737 |
|
|
2022
Q4 | $137 | Sell |
14
-25
| -64% | -$258 | ﹤0.01% | 5624 |
|
|
2022
Q3 | $1K | Sell |
39
-23
| -37% | -$469 | ﹤0.01% | 5655 |
|
|
2022
Q2 | $1K | Sell |
62
-130
| -68% | -$3.17K | ﹤0.01% | 6062 |
|
|
2022
Q1 | $7K | Sell |
192
-321
| -63% | -$18.7K | ﹤0.01% | 5693 |
|
|
2021
Q4 | $49K | Buy |
513
+174
| +51% | +$21.2K | ﹤0.01% | 5074 |
|
|
2021
Q3 | $49K | Sell |
339
-2,622
| -89% | -$401K | ﹤0.01% | 4743 |
|
|
2021
Q2 | $547K | Sell |
2,961
-1,440
| -33% | -$319K | ﹤0.01% | 3649 |
|
|
2021
Q1 | $1.08M | Buy |
4,401
+4,010
| +1,026% | +$1.02M | ﹤0.01% | 2921 |
|
|
2020
Q4 | $110K | Buy |
391
+300
| +330% | +$73.3K | ﹤0.01% | 5467 |
|
|
2020
Q3 | $22K | Sell |
91
-347
| -79% | -$84.1K | ﹤0.01% | 6128 |
|
|
2020
Q2 | $145K | Buy |
438
+368
| +526% | +$95.9K | ﹤0.01% | 5265 |
|
|
2020
Q1 | $16K | Sell |
70
-247
| -78% | -$50.8K | ﹤0.01% | 6825 |
|
|
2019
Q4 | $78K | Buy |
317
+67
| +27% | +$6.67K | ﹤0.01% | 5969 |
|
|
2019
Q3 | $14K | Hold |
250
| – | – | ﹤0.01% | 6916 |
|
|
2019
Q2 | $12K | Hold |
250
| – | – | ﹤0.01% | 7255 |
|
|
2019
Q1 | $13K | Buy |
+250
| New | +$12.6K | ﹤0.01% | 7149 |
|
|
2017
Q4 | – | Sell |
-50
| Closed | -$14K | – | 7617 |
|
|
2017
Q3 | $14K | Hold |
50
| – | – | ﹤0.01% | 6586 |
|
|
2017
Q2 | $14K | Sell |
50
-24
| -32% | -$6.87K | ﹤0.01% | 6416 |
|
|
2017
Q1 | $25K | Buy |
74
+2
| +3% | +$703 | ﹤0.01% | 6127 |
|
|
2016
Q4 | $24K | Sell |
72
-67
| -48% | -$18K | ﹤0.01% | 6459 |
|
|
2016
Q3 | $37K | Buy |
139
+36
| +35% | +$7.26K | ﹤0.01% | 5857 |
|
|
2016
Q2 | $14K | Sell |
103
-6
| -6% | -$954 | ﹤0.01% | 6377 |
|
|
2016
Q1 | $19K | Sell |
109
-9
| -8% | -$1.75K | ﹤0.01% | 6569 |
|
|
2015
Q4 | $29K | Buy |
118
+116
| +5,800% | +$30.5K | ﹤0.01% | 6287 |
|
|
2015
Q3 | $1K | Sell |
2
-57
| -97% | -$13.1K | ﹤0.01% | 7185 |
|
|
2015
Q2 | $8K | Sell |
59
-1
| -2% | -$152 | ﹤0.01% | 6568 |
|
|
2015
Q1 | $10K | Sell |
60
-15
| -20% | -$3.05K | ﹤0.01% | 6466 |
|
|
2014
Q4 | $11K | Buy |
75
+50
| +200% | +$7.12K | ﹤0.01% | 6449 |
|
|
2014
Q3 | $3K | Buy |
+25
| New | +$3.81K | ﹤0.01% | 6732 |
|
Other funds holding NGNE
SB
RG
CC
RI
EC
BBA
TECP
Citigroup's NGNE Position: Q1 2026 in Review
Citigroup increased its Neurogene (NGNE) stake by 23% in Q1 2026, buying an estimated $3.41K and bringing the position to 930 shares worth $18.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4849.
Citigroup first reported a position in NGNE in Q3 2014 and has held it in 38 quarters since. The position peaked at $1.08M in Q1 2021. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.
- Citigroup held 930 shares of Neurogene worth $18.7K as of Q1 2026.
- Citigroup bought 176 Neurogene shares in Q1 2026, an estimated $3.41K.
- Neurogene made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4849 holding.
- Citigroup first reported a position in Neurogene in Q3 2014 and has held it in 38 quarters since.
- Citigroup's Neurogene position peaked at $1.08M in Q1 2021.
- 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.